JP2013522236A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013522236A5 JP2013522236A5 JP2012557280A JP2012557280A JP2013522236A5 JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5 JP 2012557280 A JP2012557280 A JP 2012557280A JP 2012557280 A JP2012557280 A JP 2012557280A JP 2013522236 A5 JP2013522236 A5 JP 2013522236A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- biological sample
- cell
- lymphoma
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 23
- 239000012472 biological sample Substances 0.000 claims 23
- 210000003719 b-lymphocyte Anatomy 0.000 claims 17
- 108010057466 NF-kappa B Proteins 0.000 claims 14
- 102000003945 NF-kappa B Human genes 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 13
- 238000000034 method Methods 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 11
- 101001011441 Homo sapiens Interferon regulatory factor 4 Proteins 0.000 claims 8
- 102100030126 Interferon regulatory factor 4 Human genes 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 6
- 239000000090 biomarker Substances 0.000 claims 5
- 102100028122 Forkhead box protein P1 Human genes 0.000 claims 4
- 101001059893 Homo sapiens Forkhead box protein P1 Proteins 0.000 claims 4
- 101001131670 Homo sapiens PWWP domain-containing DNA repair factor 3A Proteins 0.000 claims 4
- 101000825182 Homo sapiens Transcription factor Spi-B Proteins 0.000 claims 4
- 102100022281 Transcription factor Spi-B Human genes 0.000 claims 4
- 238000001574 biopsy Methods 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims 3
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 3
- 238000012790 confirmation Methods 0.000 claims 3
- -1 4-amino-1-oxo-1,3-dihydro-isoindol-2-yl Chemical group 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 210000001185 bone marrow Anatomy 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 238000012512 characterization method Methods 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- 238000012544 monitoring process Methods 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- UQKFHCMIARRIFU-UHFFFAOYSA-N 4-amino-2-piperidin-3-yl-3h-isoindol-1-one Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCCNC1 UQKFHCMIARRIFU-UHFFFAOYSA-N 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 101100219559 Homo sapiens CARD11 gene Proteins 0.000 claims 1
- BGRDGMRNKXEXQD-UHFFFAOYSA-N Maleic hydrazide Chemical compound OC1=CC=C(O)N=N1 BGRDGMRNKXEXQD-UHFFFAOYSA-N 0.000 claims 1
- 101000687343 Mus musculus PR domain zinc finger protein 1 Proteins 0.000 claims 1
- 229940123263 Phosphodiesterase 3 inhibitor Drugs 0.000 claims 1
- 229940123304 Phosphodiesterase 7 inhibitor Drugs 0.000 claims 1
- 108010009975 Positive Regulatory Domain I-Binding Factor 1 Proteins 0.000 claims 1
- 102000009844 Positive Regulatory Domain I-Binding Factor 1 Human genes 0.000 claims 1
- 238000011529 RT qPCR Methods 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 208000037280 Trisomy Diseases 0.000 claims 1
- 150000003838 adenosines Chemical class 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229960002707 bendamustine Drugs 0.000 claims 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 claims 1
- 229960004630 chlorambucil Drugs 0.000 claims 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 1
- 238000011443 conventional therapy Methods 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims 1
- 239000002606 phosphodiesterase VII inhibitor Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 230000004083 survival effect Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31367010P | 2010-03-12 | 2010-03-12 | |
| US61/313,670 | 2010-03-12 | ||
| PCT/US2011/028097 WO2011112933A1 (en) | 2010-03-12 | 2011-03-11 | Methods for the treatment of non-hodgkin's lymphomas using lenalidomide, and gene and protein biomarkers as a predictor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013522236A JP2013522236A (ja) | 2013-06-13 |
| JP2013522236A5 true JP2013522236A5 (enExample) | 2014-04-24 |
Family
ID=43799739
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012557280A Pending JP2013522236A (ja) | 2010-03-12 | 2011-03-11 | レナリドミドを使用する非ホジキンリンパ腫の治療方法、並びに予測因子としての遺伝子及びタンパク質バイオマーカー |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20110223157A1 (enExample) |
| EP (1) | EP2544687A1 (enExample) |
| JP (1) | JP2013522236A (enExample) |
| KR (1) | KR20130038838A (enExample) |
| CN (1) | CN103068386A (enExample) |
| AR (1) | AR080505A1 (enExample) |
| AU (1) | AU2011224166B2 (enExample) |
| CA (1) | CA2792872A1 (enExample) |
| MX (1) | MX2012010367A (enExample) |
| TW (1) | TWI509247B (enExample) |
| WO (1) | WO2011112933A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120134969A1 (en) | 2009-05-25 | 2012-05-31 | Hiroshi Handa | Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells |
| EP2702410A2 (en) | 2011-04-29 | 2014-03-05 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| EP3904875B1 (en) | 2012-06-29 | 2024-11-20 | Celgene Corporation | Methods for determining drug efficacy using ikzf3 (aiolos) |
| US20150038511A1 (en) | 2012-08-09 | 2015-02-05 | Celgene Corporation | Treatment of immune-related and inflammatory diseases |
| ES2881220T3 (es) * | 2012-08-09 | 2021-11-29 | Celgene Corp | Métodos de tratamiento del cáncer usando 3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| WO2014047422A1 (en) | 2012-09-20 | 2014-03-27 | Emory University | CLASSIFIERS OF NF-kB PATHWAY ACTIVATION, DEVICES, AND METHODS OF USE THEREOF |
| BR112015026006B1 (pt) | 2013-04-17 | 2022-10-18 | Signal Pharmaceuticals, Llc | Uso de um composto em combinação com um fármaco imunomodulador imid® para tratamento ou prevenção de um câncer, composição farmacêutica e kit compreendendo os referidos compostos |
| WO2014172436A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a 5-substituted quinazolinone compound for treating cancer |
| TW201534305A (zh) | 2013-05-03 | 2015-09-16 | Celgene Corp | 使用組合療法治療癌症之方法 |
| LV14985B (lv) | 2013-10-14 | 2015-06-20 | Latvijas Organiskās Sintēzes Institūts | Lenalidomīda iegūšanas process |
| WO2015077058A2 (en) * | 2013-11-08 | 2015-05-28 | The Broad Institute, Inc. | Compositions and methods for selecting a treatment for b-cell neoplasias |
| EA201691143A1 (ru) * | 2013-12-06 | 2016-11-30 | Селджин Корпорейшн | Способы лечения гематологических злокачественных опухолей и применение биомаркеров в качестве показателя клинической чувствительности к иммуномодулирующей терапии |
| TWI745271B (zh) * | 2014-05-19 | 2021-11-11 | 美商西建公司 | 全身紅斑性狼瘡之治療 |
| US10092555B2 (en) | 2014-06-27 | 2018-10-09 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases |
| EP3347717A4 (en) | 2015-09-11 | 2019-06-05 | The Brigham and Women's Hospital, Inc. | PROCESS FOR CHARACTERIZING THE RESISTANCE TO CEREBLON MODULATORS |
| CN108368554B (zh) | 2015-09-29 | 2022-09-09 | Htg分子诊断有限公司 | 弥漫性大b细胞淋巴瘤(dlbcl)亚型分型的方法 |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| EP3399980B1 (en) | 2016-01-08 | 2025-07-16 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| US20190231757A1 (en) * | 2016-07-13 | 2019-08-01 | Takeda Pharmaceutical Company Limited | Combination of spleen tyrosine kinase inhibitors and other therapeutic agents |
| US20180238886A1 (en) * | 2017-01-31 | 2018-08-23 | Celgene Corporation | Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds |
| AU2018289539B2 (en) | 2017-06-22 | 2024-07-04 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis B virus infection |
| BR112021006318A2 (pt) | 2018-10-01 | 2021-07-06 | Celgene Corp | terapia de combinação para o tratamento de câncer |
| US12400737B2 (en) * | 2018-10-10 | 2025-08-26 | Celgene Corporation | Methods of classifying diffuse large B-cell lymphoma |
| WO2025118133A1 (zh) * | 2023-12-05 | 2025-06-12 | 浙江普洛家园药业有限公司 | 一种(s)-来那度胺-5-位衍生物及其合成方法和应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) * | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) * | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| IE58110B1 (en) * | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US4683195A (en) * | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| JPS63500636A (ja) * | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| US5073543A (en) * | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| EP0456950A1 (en) * | 1990-05-16 | 1991-11-21 | CONTRAVES ITALIANA S.p.A. | Actuator for restraint/release (R/R) devices, particularly for space applications |
| US5580578A (en) * | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) * | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US7323479B2 (en) * | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| US7393862B2 (en) * | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
| DK1505973T3 (da) * | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| CL2007002218A1 (es) * | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
| US8367633B2 (en) * | 2007-08-06 | 2013-02-05 | University Of Rochester | Methods of treating B-cell cancers |
| US7893045B2 (en) * | 2007-08-07 | 2011-02-22 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
| US20090148853A1 (en) * | 2007-12-07 | 2009-06-11 | Schafer Peter H | Biomarkers for predicting the sensitivity of cells to immunomodulatory compounds during treatment of non-hodgkin's lymphoma |
-
2011
- 2011-03-11 AU AU2011224166A patent/AU2011224166B2/en not_active Ceased
- 2011-03-11 US US13/046,527 patent/US20110223157A1/en not_active Abandoned
- 2011-03-11 KR KR1020127026568A patent/KR20130038838A/ko not_active Withdrawn
- 2011-03-11 CA CA2792872A patent/CA2792872A1/en not_active Abandoned
- 2011-03-11 JP JP2012557280A patent/JP2013522236A/ja active Pending
- 2011-03-11 AR ARP110100782A patent/AR080505A1/es unknown
- 2011-03-11 WO PCT/US2011/028097 patent/WO2011112933A1/en not_active Ceased
- 2011-03-11 CN CN2011800230775A patent/CN103068386A/zh active Pending
- 2011-03-11 EP EP11709300A patent/EP2544687A1/en not_active Withdrawn
- 2011-03-11 MX MX2012010367A patent/MX2012010367A/es not_active Application Discontinuation
- 2011-03-11 TW TW100108463A patent/TWI509247B/zh not_active IP Right Cessation
-
2015
- 2015-03-03 US US14/636,949 patent/US20150174114A1/en not_active Abandoned
- 2015-09-18 US US14/858,594 patent/US20160008344A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013522236A5 (enExample) | ||
| US12076324B2 (en) | Cancer treatments using combinations of CDK and ERK inhibitors | |
| JP6727127B2 (ja) | Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置 | |
| JP2014510078A5 (enExample) | ||
| JP2020073520A (ja) | Ｗｅｅ１阻害剤を用いた癌を処置する方法 | |
| US20140296176A1 (en) | Combination cancer therapy with an hsp90 inhibitor and an antimetabolite | |
| AU2016262079A1 (en) | Combination of analogs or derivatives of dianhydrogalactitol with platinum-containing antineoplastic agents to treat cancer | |
| RU2013145524A (ru) | Способ лечения рака с использованием 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона | |
| WO2015013579A1 (en) | Compositions to improve the therapeutic benefit of bisantrene | |
| CN104689318A (zh) | 使用braf抑制剂的治疗方法 | |
| AU2020417223A1 (en) | Treatment of cancer with CDK12/13 inhibitors | |
| Lawasut et al. | Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targets | |
| US11155879B2 (en) | Method of predicting effects of CDC7 inhibitor | |
| RU2812706C2 (ru) | Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf | |
| WO2025076109A1 (en) | Use of elesclomol to treat clear-cell ovarian cancers with mutations in arid1a | |
| WO2025207503A1 (en) | Inhibitors of polo-like kinase 4 (plk4) for the treatment of cancer | |
| TW202408514A (zh) | 用於治療癌症的表皮生長因子受體酪胺酸激酶抑制劑 | |
| WO2021247869A2 (en) | Glucocorticoid receptor gene signature | |
| Albert | Histone Deacetylase Inhibitors are Effective Therapeutic Agents in Nasopharyngeal Carcinoma Cells | |
| HK40120025A (en) | Cancer treatments using combinations of cdk and erk inhibitors | |
| HK40020609B (en) | Method of predicting effects of cdc7 inhibitor | |
| HK40020609A (en) | Method of predicting effects of cdc7 inhibitor | |
| HK1226252B (en) | Cancer treatments using combinations of cdk and erk inhibitors |